» Articles » PMID: 12942698

Serum Matrix Metalloproteinase 3 Levels in Comparison to C-reactive Protein in Periods with and Without Progression of Radiological Damage in Patients with Early Rheumatoid Arthritis

Overview
Specialty Rheumatology
Date 2003 Aug 29
PMID 12942698
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate serum matrix metalloproteinase 3 (MMP-3) levels in comparison to C-reactive protein (CRP) in periods with and without progression of radiological damage in patients with early rheumatoid arthritis (RA).

Methods: Thirty-two patients with RA and radiological progression (> or = 5 points according to the Sharp/van der Heijde method) during 6 months followed by a 6-month period without radiological progression (< or = 1 point) were selected from a prospective follow-up study of early RA patients. Serum MMP-3 levels, CRP, the erythrocyte sedimentation rate (ESR), disease activity index (DAS), swollen joint count (SJC), tender joint count (TJC), and Ritchie articular index (RAI) were measured monthly and results were transformed into mean values for the 6-month periods.

Results: During the period with radiological progression the mean serum MMP-3 correlated significantly with the mean CRP (r = 0.68, p < 0.001), ESR (r = 0.54, p = 0.001) and swollen joint count (r = 0.48, p = 0.006). In the period without radiological progression the mean serum MMP-3 only correlated with the mean CRP (r = 0.44, p = 0.012). Individual changes--expressed in percentages (%)--between the two periods showed a decrease in both the mean serum MMP-3 and CRP in 19 and an increase in 3 patients, in parallel with other markers of disease activity in these patients (69% of cases). The individual change (%) in mean serum MMP-3 or CRP did not correlate with the difference in radiological progression between the two periods.

Conclusions: Serum MMP-3 and CRP are closely related and there seems to be no difference between serum MMP-3 and CRP with regard to the monitoring of the progression of radiological damage.

Citing Articles

Matrix Metalloproteinases-3 Baseline Serum Levels in Early Rheumatoid Arthritis Patients without Initial Radiographic Changes: A Two-Year Ultrasonographic Study.

Prodanovic S, Radunovic G, Babic D, Ristic B, Sefik-Bukilica M, Zlatanovic M Med Princ Pract. 2018; 27(4):378-386.

PMID: 29794470 PMC: 6170920. DOI: 10.1159/000490350.


TRPV4 as a therapeutic target for joint diseases.

McNulty A, Leddy H, Liedtke W, Guilak F Naunyn Schmiedebergs Arch Pharmacol. 2014; 388(4):437-50.

PMID: 25519495 PMC: 4361386. DOI: 10.1007/s00210-014-1078-x.


Autoantibodies and other serological markers in rheumatoid arthritis: predictors of disease activity?.

Mota L, Dos Santos Neto L, de Carvalho J Clin Rheumatol. 2009; 28(10):1127-34.

PMID: 19597699 DOI: 10.1007/s10067-009-1223-y.


Patients with rheumatoid arthritis have an altered circulatory aggrecan profile.

Rousseau J, Sumer E, Hein G, Sondergaard B, Madsen S, Pedersen C BMC Musculoskelet Disord. 2008; 9:74.

PMID: 18507823 PMC: 2426686. DOI: 10.1186/1471-2474-9-74.


Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers.

Ates A, Turkcapar N, Olmez U, Tiryaki O, Duzgun N, Uguz E Rheumatol Int. 2007; 27(8):715-22.

PMID: 17426976 DOI: 10.1007/s00296-007-0338-1.